Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”.
14 Jun, 2021 | 08:52h | UTCImpact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine
Commentaries on Twitter
The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO
— Nature Medicine (@NatureMedicine) June 9, 2021
First-dose vaccination with the Oxford–AstraZeneca or Pfizer–BioNTech vaccine against SARS-CoV-2 reduced the incidence of new infections in the UK by 61% and 66%, respectively, according to a study in @NatureMedicine. https://t.co/2TUFE1DeII pic.twitter.com/KuMtc1cD7l
— Nature Portfolio (@NaturePortfolio) June 9, 2021